JP2022523913A5 - - Google Patents

Info

Publication number
JP2022523913A5
JP2022523913A5 JP2021544547A JP2021544547A JP2022523913A5 JP 2022523913 A5 JP2022523913 A5 JP 2022523913A5 JP 2021544547 A JP2021544547 A JP 2021544547A JP 2021544547 A JP2021544547 A JP 2021544547A JP 2022523913 A5 JP2022523913 A5 JP 2022523913A5
Authority
JP
Japan
Application number
JP2021544547A
Other languages
Japanese (ja)
Other versions
JPWO2020160458A5 (https=
JP2022523913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016192 external-priority patent/WO2020160458A1/en
Publication of JP2022523913A publication Critical patent/JP2022523913A/ja
Publication of JPWO2020160458A5 publication Critical patent/JPWO2020160458A5/ja
Publication of JP2022523913A5 publication Critical patent/JP2022523913A5/ja
Priority to JP2024231791A priority Critical patent/JP2025060943A/ja
Pending legal-status Critical Current

Links

JP2021544547A 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法 Pending JP2022523913A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231791A JP2025060943A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800096P 2019-02-01 2019-02-01
US62/800,096 2019-02-01
PCT/US2020/016192 WO2020160458A1 (en) 2019-02-01 2020-01-31 Compositions and methods for treating neurocognitive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231791A Division JP2025060943A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022523913A JP2022523913A (ja) 2022-04-27
JPWO2020160458A5 JPWO2020160458A5 (https=) 2023-04-25
JP2022523913A5 true JP2022523913A5 (https=) 2023-04-25

Family

ID=71841663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544547A Pending JP2022523913A (ja) 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法
JP2024231791A Pending JP2025060943A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231791A Pending JP2025060943A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Country Status (7)

Country Link
US (1) US20220111005A1 (https=)
EP (1) EP3917539A4 (https=)
JP (2) JP2022523913A (https=)
CA (1) CA3128003A1 (https=)
IL (1) IL285269A (https=)
MA (1) MA54874A (https=)
WO (1) WO2020160458A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
JP7013754B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
BR112021015817A2 (pt) 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
IL292382A (en) * 2019-10-22 2022-06-01 Applied Genetic Tech Corporation Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
EP4146797A1 (en) * 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2021239308A1 (en) * 2020-05-27 2021-12-02 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
JP6879413B2 (ja) * 2020-06-24 2021-06-02 株式会社三洋物産 遊技機
US20240033332A1 (en) * 2020-12-17 2024-02-01 Kyoto University Agent for activating a neuron
JP2021079226A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021087833A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
JP2021079225A (ja) * 2021-03-01 2021-05-27 株式会社三洋物産 遊技機
JP2021087836A (ja) * 2021-03-01 2021-06-10 株式会社三洋物産 遊技機
US20240342207A1 (en) * 2021-08-02 2024-10-17 Board Of Regents, The University Of Texas System Modified nucleic acid compositions and associated methods for treatment of phenylketonuria
EP4504762A1 (en) * 2022-04-08 2025-02-12 Shape Therapeutics Inc. Promoter switches for tissue-specific expression
JP7556433B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556434B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
JP7556432B2 (ja) * 2022-08-22 2024-09-26 株式会社三洋物産 遊技機
EP4680752A1 (en) * 2023-03-14 2026-01-21 UCB Biopharma SRL Gene therapy
WO2024205404A1 (en) * 2023-03-27 2024-10-03 Sanquin IP B.V. Novel capsid engineered aav vectors for liver-directed gene therapy
CN121313796A (zh) * 2025-11-24 2026-01-13 北京大学 多肽grn-e及其在制备围绝经期情绪障碍的药物或制剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495831B1 (en) * 1989-10-16 1997-01-15 Hem Pharmaceuticals Corp. Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US20050163760A1 (en) * 2001-12-06 2005-07-28 Nathalie Cartier-Lacave Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
CA2653974A1 (en) * 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
WO2007146046A2 (en) * 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
US20110203007A1 (en) * 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis
US20150352185A1 (en) * 2010-11-16 2015-12-10 Denis G. Kay Method for increasing neprilysin expression and activity
WO2017151884A1 (en) * 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia
US20210284701A1 (en) * 2016-07-14 2021-09-16 Emory University Granulin Compositions and Uses Related Thereto
AU2018236353B2 (en) 2017-03-15 2023-12-21 The Regents Of The University Of California Methods of treating lysosomal disorders
BR112021015817A2 (pt) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022523913A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)